Loading...

Aaron Goodman

Title(s)Assistant Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 2020 Oct 05; 1-14. Goldenson BH, Goodman AM, Ball ED. PMID: 32990476.
      View in: PubMed   Mentions:    Fields:    
    2. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 Oct; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422.
      View in: PubMed   Mentions:    Fields:    
    4. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol. 2020 Aug; 14(8):1680-1694. Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. PMID: 32530570.
      View in: PubMed   Mentions:    Fields:    
    5. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009.
      View in: PubMed   Mentions:
    6. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. J Oncol Pharm Pract. 2020 Jun 30; 1078155220934853. Lau KM, Saunders IM, Goodman AM. PMID: 32605497.
      View in: PubMed   Mentions:    Fields:    
    7. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 2020 Jun 24; 9(1):1781997. Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. PMID: 32923144.
      View in: PubMed   Mentions:
    8. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 May 28; 135(22):1929-1945. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. PMID: 32187362.
      View in: PubMed   Mentions: 2     Fields:    
    9. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031.
      View in: PubMed   Mentions: 1     Fields:    
    10. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020 05; 18(5):522-536. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. PMID: 32380458.
      View in: PubMed   Mentions: 1     Fields:    
    11. An IgA plasmacytoma: a rare and distinct form of plasmacytoma. Blood. 2020 Apr 23; 135(17):1505. Wang HY, Goodman AM. PMID: 32324872.
      View in: PubMed   Mentions:    Fields:    
    12. Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. JCO Precis Oncol. 2020; 4. Vu P, Khagi Y, Riviere P, Goodman A, Kurzrock R. PMID: 32923910.
      View in: PubMed   Mentions:
    13. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584.
      View in: PubMed   Mentions:
    14. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Oncologist. 2020 02; 25(2):e386-e390. Saunders IM, Goodman AM, Kurzrock R. PMID: 32043767.
      View in: PubMed   Mentions:    Fields:    
    15. Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Jul; 20(7):431-437.e2. Klebaner D, Koura D, Tzachanis D, Ball ED, Horwitz S, Goodman AM. PMID: 32284297.
      View in: PubMed   Mentions:    Fields:    
    16. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019 10; 7(10):1570-1573. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. PMID: 31405947.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    17. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18; 10(40):4018-4025. Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. PMID: 31258846.
      View in: PubMed   Mentions: 4     Fields:    
    18. Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies. J Oncol Pharm Pract. 2020 Mar; 26(2):351-360. Kim S, Namba J, Goodman AM, Nguyen T, Saunders IM. PMID: 31142232.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther. 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311.
      View in: PubMed   Mentions:
    20. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Rep. 2019 Apr; 5(4):312-316. Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R. PMID: 30989098.
      View in: PubMed   Mentions:
    22. Immune Escape of AML Cells after Transplantation. N Engl J Med. 2019 03 28; 380(13):1289. Goodman AM, Kurzrock R. PMID: 30917272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2020 Jan; 26(1):193-199. Lau KM, Saunders IM, Goodman A. PMID: 30823860.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253.
      View in: PubMed   Mentions:
    25. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019; 8(3):1550341. Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. PMID: 30723579.
      View in: PubMed   Mentions:
    26. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461.
      View in: PubMed   Mentions:
    27. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol Cancer Ther. 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions:
    28. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer. 2018 10 15; 124(20):4080-4089. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. PMID: 30204251.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018 10; 6(10):1129-1135. Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. PMID: 30194084.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    30. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. PMID: 30181172.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    31. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    32. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405.
      View in: PubMed   Mentions:
    33. Erythrodermic Psoriasis in a Man with Monoclonal B-cell Lymphocytosis. Cureus. 2017 Dec 11; 9(12):e1936. Chen SX, Hinds BR, Goodman AM, Cohen PR. PMID: 29464143.
      View in: PubMed   Mentions:
    34. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    35. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386.
      View in: PubMed   Mentions:
    36. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041.
      View in: PubMed   Mentions:
    38. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    39. What are the latest advancements in acute myeloid leukemia therapy? Future Oncol. 2017 Apr; 13(10):867-871. Goodman A, Ball ED. PMID: 28266249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis. Oncology (Williston Park). 2017 02 15; 31(2):122-4, 126-8. Goodman AM, Rust M, Costello C, Ball ED. PMID: 28205192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    42. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391.
      View in: PubMed   Mentions:
    43. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 08 15; 30(8):705-8, 710, 712. Goodman AM, Choi M, Wang L, Kurzrock R. PMID: 27535668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Aaron's Networks
    Concepts (125)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑